Kornimate/medical-research-clean huggingface dataset:
chronic neck pain and central sensizitation

Conditions: Neck Pain

Summary: chronic neck pain is one of the musculoskeletal pain problems that can cause chronic disability. it is emphasised that individuals with chronic neck pain have difficulty during different activities in their daily lives, and that this problem is a very common health problem that can lead to disability. in the case of chronic neck pain, changes in the pain threshold cause central sensitisation and individuals become more sensitive to pain stimuli. this situation can affect the processing of proprioceptive information and lead to deterioration in proprioceptive perception. this situation leads to perceptual problems in body and neck awareness. therefore, examining the relationship between the relevant parameters is important in the rehabilitation process. in this context, the aim of the study is to examine the relationship between body awareness and pain, central sensitisation, disability and proprioception in patients with chronic non-specific neck pain.

chronic neck pain is a common pain problem related to the musculoskeletal system and can lead to permanent (chronic) disability over time. in approximately 50-85% of individuals with neck pain, complaints do not completely improve despite treatment, causing the pain to become chronic. individuals with chronic neck pain have difficulty performing various activities in their daily lives, and this negatively affects their quality of life. proprioceptive feedback in the neck region, that is, sensory information that allows the body to perceive its position in space, is very important for proper control of head and neck movements. however, chronic pain can lead to a condition called central sensitization. in this case, the individual's pain threshold decreases and they become more sensitive to stimuli that would normally not cause pain. this increased sensitivity can make it difficult for the brain to process proprioceptive information correctly, which can lead to impairments in body and neck awareness. therefore, investigating the relationship between body awareness and pain level, central sensitization, disability status and proprioception in individuals with chronic non-specific neck pain is of great importance in terms of developing an effective rehabilitation program.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * being diagnosed with chronic non-specific neck pain by a doctor * being willing to participate in the study exclusion criteria: * having psychological disorders, mental disorders, cancer and severe depression * having a history of traumatic injury * having a history of primary or metastatic spinal malignancy, spinal fracture * having a neurological disease (hemiplegia, multiple sclerosis, parkinson's, etc.) * having been diagnosed with advanced osteoporosis * having a history of surgical intervention or acute infection in the cervical region
survey: covid-19 patients managed in the operating theatre of belgian hospitals

Conditions: COVID-19

Summary: covid-19 pandemic has an important impact on the health care provided by the anesthesiologists. different societies of anesthesiology have provided guidelines and recommendations on how to manage patients who have been tested positive for covid-19 or suspected to be infected. it is therefore important to know whether these guidelines have been implemented or were possible to be implemented. otherwise patients who are presenting covid-19 often show pulmonary complications. the airway management and the ventilation management of these patients can be therefore challenging and can possibly influence their outcome. it is thus important to obtain a large database with information about the characteristics of these patients, how these patients have been managed and their in-hospital outcome. information regarding the correct implementation of guidelines is as well necessary for future guidance of health care providers.


Eligibility criteria:
inclusion criteria: * all patients (pediatric/adults/parturients) who are tested positive for covid-19 or who are suspected to be infected exclusion criteria: no oral consent -
control of hypertension by non-pharmacologic means

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases

Summary: to determine whether blood pressure could be controlled by nutritional-hygienic, non-pharmacologic means in hypertensives treated with drugs in the hypertension detection and follow-up trial (hdfp).

background: in the 1970s, many studies had been conducted to control blood pressure in individuals maintained at normotensive levels by the use of weight control and sodium restriction without the concomitant use of anti-hypertensives. the associations between weight, sodium and blood pressure had been well established, but data on the relationship of intervention to blood pressure control had been less so. design narrative: patients were randomly assigned to one of three groups. the 95 patients in group i were advised to control weight, reduce sodium intake, modify dietary and alcohol intake and were removed from pharmacologic treatment. the 44 patients in group ii were removed from pharmacologic treatment, with no other intervention. the 48 patients in group iii were continued on pharmacologic treatment, with no other intervention. the primary endpoint was the proportion in groups i and ii with diastolic blood pressure less than or equal to 90 mm hg in the absence of antihypertensive drugs. secondary endpoints were average diastolic and systolic pressures. the study completion date listed in this record was obtained from the crisp legacy data.

Eligibility criteria:
men and women with controlled hypertension.
safety for 24 weeks intake of korean red ginseng in adults

Conditions: Healthy; Diabetes; Hypertension; Hyperlipidemia

Summary: korean red ginseng appears to adverse events in adults taking 24 weeks placebo and comparative assessment. and exploratory as korean red ginseng blood sugar control, reduce body fat, urti prevention, cardiovascular risk, renal function, cholesterol, improve, fatigue, and determine the impact on biological age.


Eligibility criteria:
inclusion criteria: 1. 19 years or older 2. agree to participate in this test, voluntarily signed by the parties to a written agreement 3. in the case of women of childbearing age and confirmed negative pregnancy test, you agree to contraception during the trial period applying human characters exclusion criteria: 1. pregnant and lactating mothers 2. patients with a history of hypersensitivity to contain ingredients that caused the test food 3. patients with severe renal disease (serum creatinine levels greater than 1.5 times if the upper limit of normal 4. patients with severe hepatic disease, such as cirrhosis (if ast or alt greater than three times the upper limit of normal) 5. autoimmune diseases (multiple sclerosis, lupus, rheumatoid arthritis, etc.) patients with 6. patients with uncontrolled diabetes (for hba1c 8.0% or more) 7. sulphonylureas, diabetic patients being treated with insulin 8. , uncontrolled hypertension (systolic blood pressure of 150mmhg or higher or if diastolic blood pressure greater than 100mmhg) 9. uncontrolled hyperlipidemia patients (if ldl-cholesterol is 160mg / dl or higher) 10. patients with uncontrolled thyroid dysfunction 11. patients with a dementia or psychiatric problems 12. treated with systemic steroid screening visit within 1 weeks ago 13. before the screening visit 4 weeks continuously for more than two weeks, the mentally ill and insomnia patients receiving antipsychotic medication within 14. taking the medicine within 4 weeks before the screening visit 15. taking the other investigational drugs or human test food application within four weeks before the screening visit 16. taking health supplements other than vitamins and minerals within 2 weeks before randomization 17. which means in other clinical care ∙ psychiatric disorders diseases, cardiovascular diseases, or gastrointestinal diseases, malignant tumors such as a medical condition that is likely to affect the test result is determined to be unfit to test patient participation
saizen in intra-uterine growth retardation

Conditions: Children Born With Serious Intra-uterine Growth Retardation

Summary: study of safety of saizen® in children born with serious intra-uterine growth retardation (iugr) treated to final height. an open, phase iii study involving 17 centers in france. the study enrolled children who have completed 3 or 2 years of treatment and at least one year of post treatment observation in the sponsor studies gf 4001 (safety and efficacy of saizen in the treatment of young children born with severe iugr) or gf 6283 (effect of intermittent versus continuous saizen therapy in young children born with severe iugr), respectively. detailed description: serious iugr is a syndrome characterized by low birth length and weight for gestational age (less than 10 percentile). the secretion of growth hormone in response to provocative stimuli (e.g. arginine, insulin) is normal in these children. apart from low birth weight, children born with iugr may have minor or major malformations. a catch-up period with a supraphysiological growth velocity generally occurs during the first 6 to 24 months of life in 80 to 90 percent (%) of these children. this generally allows them to reach normal height. that means that conversely, approximately 10 to 20% of children do maintain a statural handicap. puberty occurs at a normal age and the retardation in bone maturation present during the first years of life disappears very quickly. this leads to short adult stature in subjects who have not shown spontaneous catch-up during the first years of life. a safe and effective means of promoting growth without accelerating the timing or tempo of puberty would therefore be desirable.


Eligibility criteria:
inclusion criteria: * previous inclusion, good compliance and normal completion of gf4001 or gf6283 in the treatment of growth failure in children born with serious iugr (3-year continuous r-hgh treatment in gf4001 or 2-year continuous or intermittent r-hgh treatment in gf6283). * increase in height greater than 0.5 standard deviation (sd) during the first 2 years of r-hgh treatment in gf4001 or after 2 years of continuous or intermittent r-hgh treatment in gf6283. * a written informed consent at the beginning of the pre-study visit must be obtained from the parent(s)/legal guardian(s), with the understanding that consent may be withdrawn by the subject or parents at any time without prejudice to their future medical care. children able to understand the trial should personally sign and date the written informed consent, too. * other protocol-defined inclusion criteria may apply. exclusion criteria: * known multiple malformation syndrome with severe psychomotor retardation and/or body hemihypertrophy. * severe psychomotor retardation. * severe congenital malformations. * other protocol-defined exclusion criteria may apply.

Keywords: intra-uterine growth retardation (iugr) saizen recombinant human growth hormone (r-hgh) final height bone age sga (small for gestational age)
carbetocin vs. oxytocin: in-vitro myometrial contractions with and without oxytocin pre-treatment

Conditions: Postpartum Hemorrhage

Summary: the purpose of this study is to compare the ability of an isolated sample of uterine muscle tissue (in a tissue bath) to contract in the presence of various drugs. the drugs studied--uterotonics--are typically used to contract the uterus when a pregnant patient continues to bleed after delivery. oxytocin is an old standard, but seems to suffer from a desensitization phenomenon. carbetocin, a similar drug, has recently been suggested to clinicians as a replacement for oxytocin directly after certain types of cesarean section. the investigators will be testing isolated uterine muscle samples after pre-treatment with oxytocin or nothing (control) to increasing concentrations of oxytocin or carbetocin. contractile measures will be measured and compared between all groups. the investigators hypothesize that oxytocin pre-treatment will reduce contractions in both oxytocin- and carbetocin-induced contractions, and oxytocin and carbetocin will induce different patterns of contractions.

postpartum hemorrhage (pph) is a major cause of maternal mortality and morbidity. in 80% cases of pph, the primary cause is failure of the uterus to contract after delivery of the baby, which then requires further treatment of the mother with uterotonic drugs (drugs used to contract uterus and thus prevent bleeding). patients participating in this study will be asked to donate a very small sample of uterine tissue during cesarean section, which will be tested in the laboratory for the ability to contract in response to the uterotonics oxytocin and carbetocin. we will seek to better understand the effects of these drugs by comparing their contractile capability in isolated uterine tissue.

Eligibility criteria:
inclusion criteria: * gestational age 37-41 weeks * non-laboring patients, not exposed to exogenous oxytocin * patients requiring primary or first repeat cesarean section * cesarean section under spinal anesthesia exclusion criteria: * patients who require general anesthesia * patient who had previous myometrial surgery or more than one previous cesarean section * patients with placental anomalies * emergency cesarean section in labor * patients with multiple pregnancy (twins, etc.)

Keywords: uterine contraction dose response oxytocin pretreatment oxytocin carbetocin
high-definition transcranial electrical stimulation for fibromyalgia

Conditions: Fibromyalgia

Summary: transcranial electrical stimulation (tces) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. the tces has been applied in clinical trials related to rehabilitation research in recent years, and the safety and effectiveness have also been established. however, the existing tces products effect on the whole brain networks and lack special waveforms. the investigators developed a wearable high-definition tces (hd-tces) with special waveforms. this novel stimulation system will result in more precise and focal stimulation of selected brain regions with special waveforms to display better neuromodulation performance. in this study, the investigators will preliminarily examine the effects and safety of the hd-tces in patients with fibromyalgia. the investigators expect that the hd-tces will relief pain, improve sleep quality, emotion, and general health of the patients.


Eligibility criteria:
inclusion criteria: 1. with a diagnosis of fibromyalgia. 2. age ≥ 20 years. 3. a mean pain score ≥ 4 on a 11-point numeric rating scale during the 2 weeks preceding the trial. exclusion criteria: 1. intolerance to electrical stimulation. 2. a history of arrhythmia. 3. implantable medical electronic devices (e.g., like pacemaker). 4. metal implants in the head or neck. 5. wounds on the skin of head. 6. a history of brain surgery or severe brain trauma. 7. severe cognitive or psychiatric disorders (e.g., schizophrenia, depression or bipolar disorder). 8. a history of seizure or other brain pathology. 9. drug or alcohol abuse. 10. malignant neoplasm or rheumatism disorder (e.g., sle, ra, as, ibd) 11. pregnancy. 12. change in medication of fibromyalgia within 1 week prior the trial. 13. pregnant or breastfeeding women. 14. intra-cerebral lesions (such as brain tumors, arteriovenous tumors). 15. history of encephalitis or meningitis.

Keywords: fibromyalgia transcranial electrical stimulation analgesic effect
ai in gim diagnosis

Conditions: GIM Diagnosis; Artificial Intellegence

Summary: this study will use artificial intelligence (ai) for diagnosing gastric intestinal metaplasia.

the patients with previously diagnose gastric intestinal metaplasia (gim) and have the surveillance gastroscopy will be enrolled. the routine surveillance program will be performed additional to taking photo at both gim and normal mucosa at least 5 pictures in each. biopsy will be done to confirm the diagnosis of gim and normal mucosa. all pictures will be inserted to ai algorithm based on the convolutional neural network (cnn). then, the ai program will be validated in daily endoscopy compared with pathology. accuracy, sensitivity and specificity can be calculated by 2x2 table.

Eligibility criteria:
inclusion criteria: * more than 18 years of age * able to sign a consent form exclusion criteria: * history of gastric surgery * coagulopathy * pregnancy/breast feeding
early diagnosis of patients with mild cognitive impairment through the parameterization of functional tests.

Conditions: Mild Cognitive Impairment

Summary: the present study aims to develop an index formed by the variables, functional tests, scales and instruments that best discriminate between healthy subjects and subjects with mci and that allows the stratification of different levels of severity of mci, and to validate new systems for the early diagnosis of subjects with mild cognitive impairment.

dementia affects 46.8 million people and in 2050 it is expected that there will be between 115-135 million people suffering from dementia. inside dementias, mild cognitive impairment (mci) has a prevalence in adults aged ≥65 years of 10-20%. patients with mci also show greater progression towards dementia, higher mortality and disability, and a greater use of medical care compared to cognitively normal subjects that converts mci into an important public health problem, which reinforces the need to perfect clinic assessment procedures to improve the early identification of individuals with mci. early diagnosis could allow effective medical treatments that prevent or slow the onset of dementia, and could improve the effectiveness of non-pharmacological interventions. currently, it can be used an inertial sensor and 3d motion capture systems with a camera to analyse kinematics and these instruments are being integrated as a rehabilitation tool in patients. the use of inertial sensor and 3d motion capture cameras would help to find fast and cheap assessment methods for professionals.

Eligibility criteria:
inclusion criteria: * subjects over 60 years of age. * healthy subjects and subjects diagnosed with mild cognitive impairment. * subjects able of filling out questionnaires and performing functional tests. exclusion criteria: * participants with neurological pathologies other than mild cognitive impairment. * participation in an experimental study where they receive a treatment. * score on the mini-mental state examination of less than 24. * inability to get up from the chair at least 5 times or 30 seconds * inability to walk 20 meters. * inability to raise up both arms to 90 degrees or lifting 2 kg with the hand. * inability to walk independently without a walking assistance device (cane, crutch or walker). * patients with prescription of beta-blockers. * inability to provide informed consent.

Keywords: mild cognitive impairment diagnosis functional tests kinematics validation reliability
phosphate binder-combination study of khk7791 in hyperphosphatemia patients on hemodialysis

Conditions: Hyperphosphatemia

Summary: to evaluate the efficacy of khk7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of khk7791 30 mg in combination with phosphate binders for 6 weeks and those receiving placebo in combination with phosphate binders.


Eligibility criteria:
inclusion criteria: 1. has voluntarily provided written informed consent to participate in the study. 2. aged ≥ 20 years (expressed in completed years) at the time of providing informed consent. 3. stable chronic renal failure patients who have undergone hemodialysis 3 times per week for at least 12 weeks until screening examination. 4. dialysis conditions, excluding dry weight, should have been unchanged during the last 2 weeks before screening examination. 5. the prescribed drug and dosage regimen should have been unchanged during the last 4 weeks before screening examination. 6. serum phosphorus levels should be in the range of ≥ 3.5 and ≤ 6.0 mg/dl at screening examination. 7. if on any vitamin d, calcimimetics regimen, bisphosphonate,calcitonin preparations, selective estrogen receptor modulators or teriparatide preparations then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination. 8. kt/v urea ≥ 1.2 at the most recent test in routine medical practice before screening examination. exclusion criteria: 1. peritoneal dialysis was performed within 12 weeks before screening examination. 2. ipth \>600 pg/ml (should be based on the most recent value from the patients' medical records, etc. before pre-enrollment) 3. having concurrent or a history of inflammatory bowel disease (ibd) or diarrhea-predominant irritable bowel syndrome 4. history of gastrectomy or enterectomy or having undergone gastrointestinal tract surgery within 3 months before screening examination. 5. subjects who used anti rankl preparations within 6 weeks before screening examination. 6. subjects who used anti-sclerostin antibody preparations within 12 weeks before screening examination. 7. having concurrent severe heart disease or hepatic impairment. 8. developed cerebrovascular disease requiring hospitalization within 6 months before screening examination. 9. uncontrollable hypertension or diabetes. 10. scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period. 11. any diagnosis of and treatment of malignancy within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).

Keywords: tenapanor hyperphosphatemia hemodialysis
impact of fluid resuscitation protocol on the incidence of reoperation for bleeding after emergency cardiopulmonary bypass grafting

Conditions: Resternotomy

Summary: this is a retrospective data analysis of patients that underwent elective or emergency cardiopulmonary bypass. resternotomy due to bleeding is frequent after sternotomy. also due to implementation of argipressin into clinical practice fluid resuscitation protocol has changed to more vasopressors and less fluid within the past five years. the investigators want to explore the influence of volume resuscitation protocol on incidence of rethoracotomy during the past twenty years.


Eligibility criteria:
inclusion criteria: * all patients that underwent elective or emergency aortocoronary bypass at the university hospital basel between 2009 and 2020. exclusion criteria: * none.